CA2859281C - Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters - Google Patents

Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters Download PDF

Info

Publication number
CA2859281C
CA2859281C CA2859281A CA2859281A CA2859281C CA 2859281 C CA2859281 C CA 2859281C CA 2859281 A CA2859281 A CA 2859281A CA 2859281 A CA2859281 A CA 2859281A CA 2859281 C CA2859281 C CA 2859281C
Authority
CA
Canada
Prior art keywords
formula
compound
process according
iii
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2859281A
Other languages
English (en)
French (fr)
Other versions
CA2859281A1 (en
Inventor
Jacques Tonnel
Tony Pintus
Alain Burgos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CA2859281A1 publication Critical patent/CA2859281A1/en
Application granted granted Critical
Publication of CA2859281C publication Critical patent/CA2859281C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2859281A 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters Active CA2859281C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201121557A GB201121557D0 (en) 2011-12-15 2011-12-15 Process
GB1121557.1 2011-12-15
PCT/GB2012/000903 WO2013088108A1 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters

Publications (2)

Publication Number Publication Date
CA2859281A1 CA2859281A1 (en) 2013-06-20
CA2859281C true CA2859281C (en) 2020-10-27

Family

ID=45560499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859281A Active CA2859281C (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters

Country Status (27)

Country Link
US (1) US9102658B2 (https=)
EP (1) EP2791129B1 (https=)
JP (2) JP6300277B2 (https=)
KR (1) KR102018929B1 (https=)
CN (1) CN104114548B (https=)
AU (1) AU2012351341B2 (https=)
BR (1) BR112014014604B1 (https=)
CA (1) CA2859281C (https=)
CY (1) CY1117087T1 (https=)
DK (1) DK2791129T3 (https=)
EA (1) EA026617B1 (https=)
ES (1) ES2557762T3 (https=)
GB (1) GB201121557D0 (https=)
HR (1) HRP20151422T1 (https=)
HU (1) HUE028257T2 (https=)
IL (1) IL233132A (https=)
ME (1) ME02348B (https=)
MX (1) MX342273B (https=)
PL (1) PL2791129T3 (https=)
PT (1) PT2791129E (https=)
RS (1) RS54523B1 (https=)
SG (1) SG11201402798RA (https=)
SI (1) SI2791129T1 (https=)
SM (1) SMT201500327B (https=)
UA (1) UA111868C2 (https=)
WO (1) WO2013088108A1 (https=)
ZA (1) ZA201404246B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) * 2011-12-15 2012-01-25 Oxagen Ltd Process
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
US20220184060A1 (en) 2018-12-27 2022-06-16 Chiesi Farmaceutici S.P.A. Pharmaceutical composition comprising spherical agglomerates of timapiprant
CN111978245A (zh) * 2020-09-15 2020-11-24 上海毕得医药科技有限公司 一种3-氟-2-异丁基吡啶的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283139A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US7188489B2 (en) 2005-04-12 2007-03-13 Martello Russell A Portable air conditioner
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
US7999119B2 (en) 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
US20110124683A1 (en) 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
AU2009204700B2 (en) 2008-01-18 2013-07-04 Atopix Therapeutics Limited Compounds having CRTH2 antagonist activity
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis

Also Published As

Publication number Publication date
EA201490998A1 (ru) 2014-11-28
KR102018929B1 (ko) 2019-09-05
SG11201402798RA (en) 2014-06-27
BR112014014604A2 (pt) 2017-06-13
DK2791129T3 (en) 2015-12-14
JP2015500325A (ja) 2015-01-05
HRP20151422T1 (hr) 2016-02-26
JP6300277B2 (ja) 2018-03-28
GB201121557D0 (en) 2012-01-25
MX2014007129A (es) 2014-09-04
BR112014014604B1 (pt) 2021-01-12
PL2791129T3 (pl) 2016-05-31
KR20140113927A (ko) 2014-09-25
EA026617B1 (ru) 2017-04-28
SMT201500327B (it) 2016-02-25
RS54523B1 (sr) 2016-06-30
HUE028257T2 (en) 2016-12-28
EP2791129A1 (en) 2014-10-22
CY1117087T1 (el) 2017-04-05
US9102658B2 (en) 2015-08-11
AU2012351341B2 (en) 2017-08-24
EP2791129B1 (en) 2015-10-07
CN104114548A (zh) 2014-10-22
MX342273B (es) 2016-09-21
AU2012351341A1 (en) 2014-07-24
PT2791129E (pt) 2016-01-26
ES2557762T3 (es) 2016-01-28
CN104114548B (zh) 2016-01-20
ME02348B (me) 2016-06-20
JP2018008985A (ja) 2018-01-18
NZ626732A (en) 2015-09-25
WO2013088108A1 (en) 2013-06-20
IL233132A (en) 2015-09-24
UA111868C2 (uk) 2016-06-24
IL233132A0 (en) 2014-08-03
HK1197671A1 (zh) 2015-02-06
SI2791129T1 (sl) 2016-02-29
US20140350264A1 (en) 2014-11-27
CA2859281A1 (en) 2013-06-20
ZA201404246B (en) 2016-10-26

Similar Documents

Publication Publication Date Title
CA2859281C (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
US20220162227A1 (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2009010988A1 (en) An improved, industrially viable process for the preparation of high purity paliperidone
WO2008087557A2 (en) An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
AU2012324824B2 (en) Processes for the preparation of 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and of its precursors
JP2015500325A5 (https=)
JP3930736B2 (ja) ピリジンメタノール化合物の製造方法
KR20090119828A (ko) 4,4´-(1-메틸-1,2-에탄디일)-비스-(2,6-피페라진디온)의 신규 제조 방법
JPWO2001042240A1 (ja) ピリジンメタノール化合物の製造方法
CN104837817B (zh) 制备3‑氨基‑哌啶化合物的合成路线
HK1197671B (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
NZ626732B2 (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
EP3794001B1 (en) Intermediates and processes for the preparation of linagliptin and its salts
NO330042B1 (no) Fremgangsmate til fremstilling av sure salter av gemifloksasin og mellomprodukt for fremstilling av samme.
WO2010082110A2 (en) Novel process for preparing pure 6-fluoro-3-piperidin-4-yl-1,2-benzisoxazole hydrochloride and its conversion to paliperidone
CN121773111A (zh) 吡嗪并萘啶二酮类化合物的制备方法及其中间体
CN121930185A (zh) 一种钆特醇异构体的制备方法
HK40029630B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
HK40029630A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171211

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240726